Recent news items associated with the company’s ticker primarily concern agricultural commodity market movements and dividend runs of unrelated companies, providing no direct insight into Yubo International Biotech Ltd’s business activities.

• Wheat prices rallied as Russia rejected Ukraine’s proposal, impacting commodity markets [N1].
• Multiple articles discuss upcoming dividend runs for various financial institutions unrelated to Yubo International Biotech Ltd [N2][N3][N4][N5][N6].
• Wheat bulls put a premium heading into the weekend, reflecting commodity market strength [N7].
• Cotton markets showed strength heading into the weekend [N8].

Not applicable due to lack of disclosed operational or strategic information.

The company exhibits financial challenges with no reported revenue and a net loss, alongside liquidity constraints indicated by a low current ratio. Regulatory risks include potential delisting under the Holding Foreign Companies Accountable Act if audit inspections are restricted. PRC tax residency classification and foreign exchange controls pose additional risks to dividend payments and capital flows. Lack of transparency on business operations and industry further increases uncertainty.

There is insufficient public information to assess Yubo International Biotech Ltd’s competitive advantages or moat. The company’s disclosures focus on regulatory and tax risks rather than operational or market positioning details.

• Regulatory and Audit Inspection Risks: The company is subject to the Holding Foreign Companies Accountable Act, which could lead to delisting if its auditor is not fully inspected by the PCAOB. Although the auditor is PCAOB-registered, future inspection access issues could impact trading status [S1].
• PRC Tax Residency and Withholding Risks: Uncertainty exists regarding the company’s classification as a PRC resident enterprise for tax purposes, which could result in unfavorable tax consequences including withholding taxes on dividends and capital gains for non-resident shareholders [S1].
• Foreign Exchange and Dividend Restrictions: PRC foreign exchange controls may limit the company’s ability to convert RMB to foreign currency and remit dividends to shareholders, potentially affecting returns [S1].
• Compliance with PRC Foreign Exchange Registration: Failure of PRC resident beneficial owners to comply with SAFE registration requirements may restrict capital contributions and dividend distributions, posing operational and financial risks [S1].
• Liquidity Constraints: As of June 30, 2026, the company’s current liabilities significantly exceed current assets, with a current ratio of 0.18, indicating potential short-term liquidity challenges [S2].

• Yubo International Biotech Ltd is a publicly traded company with ticker YBGJ.
• The company reported zero revenue and a net loss of $247,949 for the quarter ended June 30, 2026, according to its 10-Q filing dated August 14, 2026 [S2].
• As of June 30, 2026, the company had cash and cash equivalents of $11,989 and current assets of $583,098, with current liabilities of $3,327,598, resulting in a current ratio of 0.18 and a cash ratio of 0, indicating liquidity constraints [S2].
• The company’s auditor is HCL PLLC, a PCAOB-registered firm headquartered in the United States, subject to regular PCAOB inspections [S1].
• The company faces regulatory risks under the Holding Foreign Companies Accountable Act related to audit inspections and potential delisting [S1].
• Yubo International Biotech Ltd operates subsidiaries in the PRC and Hong Kong, with complex tax considerations including potential PRC withholding taxes on dividends and risks related to classification as a PRC resident enterprise for tax purposes [S1].
• The company is subject to PRC foreign exchange controls that may restrict its ability to convert RMB to foreign currency and remit dividends to shareholders [S1].
• PRC regulations require PRC resident shareholders to register offshore investments, and non-compliance may limit capital contributions and dividend distributions [S1].
• The company has not disclosed detailed information about its business model, industry, or country of incorporation beyond the PRC and Hong Kong context [S1,S2].
• Recent news articles associated with the company’s ticker do not relate to its business but rather to agricultural commodity market developments and dividend runs of unrelated companies [N1][N2][N3][N4][N5][N6][N7][N8].